Plasma Fractionation Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2026

Published on : May-2020 | List of Tables : 37 | List of Figures : 77 | No. of Pages : 170 | Report Code : FACT4806MR | Format :

Plasma Fractionation Market Outlook:

Plasma derived immunoglobulins are being increasingly used in multiple clinical indications such as autoimmune and inflammatory diseases. The plasma fractionation market has heavily invested in therapies such as Ceruloplasmin, IgA and Plasmin. In addition, burgeoning investments in innovation and technological advancements in efficient and cost-effective procedures for fractioning proteins shall give impetus to the market.

On the back of the aforementioned trends, the global plasma fractionation market is poised to experience an uptick in the forecast period (2020-2026). Anticipated CAGR for the market is pegged at a staggering 7.1%. The COVID-19 pandemic is anticipated to generate potential growth opportunities for the plasma fractionation market. This is attributed to the efforts by key players to collaborate on convalescent plasma (CP) extraction and study its effects on COVID-19 patients.

Plasma Fractionation Market Share Analysis by Application:

The neurology segment is anticipated to enjoy the lion’s share of the plasma fractionation market. A spurt in neurological disorders is responsible for the growing scope of the neurology segment. Fact.MR projects that neurological disorders plague more than 450 million people globally. The neurology segment shall account for more than two-fifths of the plasma fractionation market, leveraging at a CAGR of 7.2%.

Trailing behind is the immunology segment, expanding 1.5x during the forecast period. Rising popularity of immunoglobulins as an important treatment option for autoimmune and inflammatory diseases is anticipated to be a key growth driver. The immunology segment is anticipated to capture almost one-third of the plasma fractionation market, reaching a value of US$ 10 Bn by the end of 2026. 

plasma fractionation market 01

To get the latest COVID-19 impact insights on the plasma fractionation market, ask an analyst here

Plasma Fractionation Market Analysis by Region:

The North American plasma fractionation market shall lay suzerainty during the forecast period. The North American region is set to capture nearly 2/5th of the plasma fractionation market, expanding at a CAGR of 6.6%. A robust healthcare sector along with continuous technological innovation shall accelerate demand for plasma fractionation in North America. Moreover, the prevalence of neurological and autoimmune diseases as well as hemophilia shall boost demand prospects for plasma fractionation.

Asia-Pacific shows a promising outlook for the growth of the plasma fractionation market. Therapeutic applicability of plasma fractionation proteins is an important growth lever for the Asia-Pacific market. Moreover, technological improvements in healthcare sectors of emerging economies are anticipated to pave way for exciting market prospects during the forecast period. Projected CAGR for the Asia-Pacific market is pegged at a staggering 8.0%. Also, prevalence of immune and bleeding disorders have prompted investments in plasma fractionation techniques. 

plasma fractionation market 02

Access our exhaustive repertoire of in-depth regional insights on the plasma fractionation market by requesting for a report sample here

Plasma Fractionation Companies: Nuanced Research Trump Card for Key Players

The plasma fractionation market consists of multiple players. These are: CSL Behring, Shire plc, Sanquin, Biotest AG, GRIFOLS, Baxter International Inc., Kedrion, Octapharma USA Inc. to name a few. Innovative product offerings and new product development are key growth strategies adopted by market players.

CSL Behring, for instance, markets the Privigen, Carimune, Snadoglobulin and Hizentra solutions. Sanquin produces four types of plasma products using various isolation techniques: coagulation factors, protease inhibitors, immunoglobulins and albumin. The company also offers contract fractionation services.

Biotest AG develops, manufactures and markets plasma proteins and biotherapeutic drugs. It leads in the field of plasma collection. Biotest AG presently develops plasma proteins for Primary Immune Deficiency (PID) and various hyperimmune products. Examples of the products offered are Varitect, Cytotect CP and Albiomin.

COVID-19 Market Insights:

The COVID-19 pandemic is set to offer significant growth opportunities for the plasma fractionation market. Several countries are experimenting with plasma fractionation techniques to find potential cures and diagnostic methodologies for the novel coronavirus. A potential method of curing COVID-19 positive patients is the usage of convalescent plasma (CP). The plasma is extracted from the blood of a formerly infected person and then administered to an existing patient. The patient therefore acquires passive immunization as the plasma is said to contain critical antibodies to fight the virus.

Octapharma, a leading pharmaceutical company, is putting its expertise to work to find new treatments for COVID-19. It is doing so by collaborating with leading plasma fractionation players in order to develop a potential plasma-derived hyperimmune immunoglobulin therapy. The alliance is investigating the development of one unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine. The medicine has the potential to treat patients with severe COVID-19 symptoms. The alliance includes companies such as CSL Behring, Takeda BPL, Biotest and LFB.  

Likewise, Grifols has entered into a formal collaboration with the United States Biomedical Advanced Research Department Authority (BARDA), the FDA and other federal public health authorities. The company is collecting convalescent plasma to support the necessary preclinical and clinical studies to determine if the anti-SARS-CoV-2 hyperimmune immunoglobulin is effective to treat COVID-19.

Analyst’s Viewpoint:

The plasma fractionation market is poised to embark on a positive growth trajectory. Rising technological innovation and augmenting demand for plasma proteins are credited as important growth drivers. Moreover, the COVID-19 pandemic has prompted market players to invest in developing plasma-based solutions to eradicate the disease. Regionally, North America is poised to retain market hegemony while Asia-Pacific promises attractive growth opportunities.

Plasma Fractionation Market: Report Scope:

The recent study by Fact.MR on plasma fractionation incorporates a six-year forecast period, elucidating on the potential drivers, opportunities and restraints across key segments and regions. The plasma fractionation market has been segmented on the basis of product type, application and end-users. Each segment contains a detailed analysis of their market share and revenue.

A detailed regional analysis for five geographies has been embedded in the report. These regions are North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA). Each region includes the segmental analysis highlighted above. In addition, a competition landscape has also been included. This section provides details about the key market players, their revenue, and their strategies for expansion and product launches. Moreover, a SWOT analysis has been provided to provide a realistic picture for future prospects of the market players. 

Plasma Fractionation Market- Scope of the Report

The recent study by Fact.MR on plasma fractionation market offers a 6-year forecast between 2020 and 2026. The study analyzes crucial trends that are currently determining the growth of the plasma fractionation market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders and emerging players associated with the provision of plasma fractionation services. The study also provides dynamics that are responsible for influencing the future status of the plasma fractionation market over the forecast period.

A detailed assessment of the plasma fractionation market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the plasma fractionation market along with their product portfolio enhances the reliability of this comprehensive research study.

Plasma Fractionation Market: Report Summary

The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in the plasma fractionation market across the globe.

A comprehensive estimate on the plasma fractionation market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of plasma fractionation market during the forecast period.

 Plasma Fractionation Market Segmentation

Fact.MR has studied the plasma fractionation market with detailed segmentation on the basis of product, application, end-user and region.

Product

Application

End-user

Region

Immunoglobulins:

  • Intravenous Immunoglobulins
  • Subcutaneous Immunoglobulins

Neurology

Hospitals & Clinics

North America

Coagulation Factor Concentrates:

  • Factor VIII
  • Factor IX
  • Factor XIII
  • Prothrombin Complex Concentrate
  • Von Willebrand Factor (VWF)
  • Fibrinogen Concentrates

Immunology

Clinical Research Laboratories

Europe

Albumin

Hematology

Academic Institutions

Asia Pacific

Protease Inhibitors

Critical Care

 

Latin America

Other Plasma Products

Pulmonary

 

Middle East & Africa

 

Other Applications

 

 

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”

Plasma Fractionation Market: Analysis on Market Size Evaluation

The plasma fractionation market has been analyzed for each market segment, in terms of value (US$ Mn). 

Market estimates at global and regional levels for Plasma fractionation market is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent plasma fractionation market segments, along with market attractiveness evaluation has been incorporated in the report.

Plasma Fractionation Market: Inspected Assessment on Regional Segments

Key sections have been elaborated in the plasma fractionation report, which have helped deliver projection on the regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of the plasma fractionation market during the forecast period.

Country-specific valuation on demand for plasma fractionation has been offered for each regional market, along with the market scope estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value for emerging countries has also been included in the report.

Plasma Fractionation Market: In-Depth Analysis on Competitive Landscape

The report sheds light on the leading manufacturers of plasma fractionation products along with their detailed profiles. Essential and up-to-date data information related to the market performers, who are principally engaged in the production of plasma fractionation products, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, such as product portfolio, key strategies along with an all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the plasma fractionation market. Prominent manufacturers with established market presence in global Plasma fractionation market are GRIFOLS, Sanquin, CSL Behring Limited, Shire Plc., Biotest AG, Baxter International, etc. 

1. Preface

     1.1. Market Definition and Scope

     1.2. Market Segmentation

     1.3. Key Research Objectives

     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Plasma Fractionation Market

4. Market Overview

     4.1. Introduction

     4.2. Overview

     4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

     4.4. Global Plasma Fractionation Market Analysis and Forecast, 2020–2026

5. Market Outlook

     5.1. Regional Distribution of Fractionation Plants

     5.2. Regional Distribution of Fractionation Throughput

     5.3. Worldwide IVIG Unit Sales by Region

     5.4. Worldwide Albumin Unit Sales by Region

     5.5. Plasma Proteins and their Clinical Significance

     5.6. Value Chain Analysis

6. Global Plasma Fractionation Market Analysis and Forecast, by Product Type

     6.1. Introduction & Definition

     6.2. Key Findings / Developments

     6.3. Global Plasma Fractionation Market Value Forecast, by Product Type, 2020–2026

            6.3.1. Immunoglobulin

                 6.3.1.1. Intravenous Immunoglobulin

                 6.3.1.2. Subcutaneous Immunoglobulin

            6.3.2. Coagulation Factor Concentrates

                 6.3.2.1. Factor VIII

                 6.3.2.2. Factor IX

                 6.3.2.3. Factor XIII 

                 6.3.2.4. Prothrombin Complex Concentrates

                 6.3.2.5. Von Willebrand Factor (VWF)

                 6.3.2.6. Fibrinogen Concentrates

            6.3.3. Albumin

            6.3.4. Protease Inhibitors

            6.3.5. Other Plasma Products

     6.4. Global Plasma Fractionation Market Attractiveness, by Product Type

7. Global Plasma Fractionation Market Analysis and Forecast, by Application

     7.1. Introduction & Definition

     7.2. Global Plasma Fractionation Market Value Forecast, by Application, 2020–2026

            7.2.1. Neurology

            7.2.2. Immunology

            7.2.3. Hematology

            7.2.4. Critical Care

            7.2.5. Pulmonology

            7.2.6. Other Applications

     7.7. Global Plasma Fractionation Market Attractiveness, by Product 

8. Global Plasma Fractionation Market Analysis and Forecast, by End-user

     8.1. Introduction & Definition

     8.2. Global Plasma Fractionation Market Value Forecast, by End-user, 2020–2026

            8.2.1. Hospitals and Clinics

            8.2.2. Clinical Research Laboratories

            8.2.3. Academic Institutes

9. Global Plasma Fractionation Market Analysis and Forecast, by Region 

     9.1. Global Market Scenario

     9.2. Global Plasma Fractionation Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe 

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

     9.3. Global Plasma Fractionation Market Attractiveness, by Region

10. North America Plasma Fractionation Market Analysis and Forecast

     10.1. Introduction

     10.2. North America Plasma Fractionation Market Value Forecast, by Product Type, 2020–2026

            10.2.1. Immunoglobulin

                 10.2.1.1. Intravenous Immunoglobulin

                 10.2.1.2. Subcutaneous Immunoglobulin

            10.2.2. Coagulation Factor Concentrates

                 10.2.2.1. Factor VIII

                 10.2.2.2. Factor IX

                 10.2.2.3. Factor XIII 

                 10.2.2.4. Prothrombin Complex Concentrates

                 10.2.2.5. Von Willebrand Factor (VWF)

                 10.2.2.6. Fibrinogen Concentrates

            10.2.3. Albumin

            10.2.4. Protease Inhibitors

            10.2.5. Other Plasma Products

     10.3. North America Plasma Fractionation Market Value Forecast, by Application, 2020–2026

            10.3.1. Neurology

            10.3.2. Immunology

            10.3.3. Hematology

            10.3.4. Critical Care

            10.3.5. Pulmonology

            10.3.6. Other Applications

     10.4. North America Plasma Fractionation Market Value Forecast, by End-user, 2020–2026

             10.4.1. Hospitals and Clinics

              10.4.2. Clinical Research Laboratories

              10.4.3. Academic Institutes

     10.5. North America Plasma Fractionation Market Value Forecast, by Country, 2020–2026

            10.5.1. U.S.

            10.5.2. Canada

     10.6. North America Plasma Fractionation Market Attractiveness Analysis 

            10.6.1. By Product

            10.6.2. By Application

            10.6.3. By End-user

            10.6.4. Country

11. Europe Plasma Fractionation Market Analysis and Forecast

     11.1. Introduction

     11.2. Europe Plasma Fractionation Market Value Forecast, by Product Type, 2020–2026

            11.2.1. Immunoglobulin

                 11.2.1.1. Intravenous Immunoglobulin

                 11.2.1.2. Subcutaneous Immunoglobulin

            11.2.2. Coagulation Factor Concentrates

                 11.2.2.1. Factor VIII

                 11.2.2.2. Factor IX

                 11.2.2.3. Factor XIII 

                 11.2.2.4. Prothrombin Complex Concentrates

                 11.2.2.5. Von Willebrand Factor (VWF)

                 11.2.2.6. Fibrinogen Concentrates

            11.2.3. Albumin

            11.2.4. Protease Inhibitors

            11.2.5. Other Plasma Products

     11.3. Europe Plasma Fractionation Market Value Forecast, by Application, 2020–2026

            11.3.1. Neurology

            11.3.2. Immunology

            11.3.3. Hematology

            11.3.4. Critical Care

            11.3.5. Pulmonology

            11.3.6. Other Applications

     11.4. Europe Plasma Fractionation Market Value Forecast, by End-user, 2020–2026

              11.4.1. Hospitals and Clinics

              11.4.2. Clinical Research Laboratories

              11.4.3. Academic Institutes

     11.5. Europe Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2020–2026

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

     11.6. Europe Plasma Fractionation Market Attractiveness Analysis 

            11.6.1. By Product

            11.6.2. By Application

            11.6.3. By End-user

              11.6.4. Country 

12. Asia Pacific Plasma Fractionation Market Analysis and Forecast

     12.1. Introduction

     12.2. Asia Pacific Plasma Fractionation Market Value Forecast, by Product Type, 2020–2026

            12.2.1. Immunoglobulin

                 12.2.1.1. Intravenous Immunoglobulin

                 12.2.1.2. Subcutaneous Immunoglobulin

            12.2.2. Coagulation Factor Concentrates

                 12.2.2.1. Factor VIII

                 12.2.2.2. Factor IX

                 12.2.2.3. Factor XIII 

                 12.2.2.4. Prothrombin Complex Concentrates

                 12.2.2.5. Von Willebrand Factor (VWF)

                 12.2.2.6. Fibrinogen Concentrates

            12.2.3. Albumin

            12.2.4. Protease Inhibitors

            12.2.5. Other Plasma Products

     12.3. Asia Pacific Plasma Fractionation Market Value Forecast, by Application, 2020–2026

            12.3.1. Neurology

            12.3.2. Immunology

            12.3.3. Hematology

            12.3.4. Critical Care

            12.3.5. Pulmonology

            12.3.6. Other Applications

     12.4. Asia Pacific Plasma Fractionation Market Value Forecast, by End-user, 2020–2026

              12.4.1. Hospitals and Clinics

              12.4.2. Clinical Research Laboratories

              12.4.3. Academic Institutes 

     12.5. Asia Pacific Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2020–2026

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

     12.6. Asia Pacific Plasma Fractionation Market Attractiveness Analysis 

             12.6.1. By Product

             12.6.2. By Application

             12.6.3. By End-user

             12.6.4. Country 

13. Latin America Plasma Fractionation Market Analysis and Forecast

     13.1. Introduction

     13.2. Latin America Plasma Fractionation Market Value Forecast, by Product Type, 2020–2026

            13.2.1. Immunoglobulin

                 13.2.1.1. Intravenous Immunoglobulin

                 13.2.1.2. Subcutaneous Immunoglobulin

            13.2.2. Coagulation Factor Concentrates

                 13.2.2.1. Factor VIII

                 13.2.2.2. Factor IX

                 13.2.2.3. Factor XIII 

                 13.2.2.4. Prothrombin Complex Concentrates

                 13.2.2.5. Von Willebrand Factor (VWF)

                 13.2.2.6. Fibrinogen Concentrates

            13.2.3. Albumin

            13.2.4. Protease Inhibitors

            13.2.5. Other Plasma Products

     13.3. Latin America Plasma Fractionation Market Value Forecast, by Application, 2020–2026

            13.3.1. Neurology

            13.3.2. Immunology

            13.3.3. Hematology

            13.3.4. Critical Care

            13.3.5. Pulmonology

            13.3.6. Other Applications

     13.4. Latin America Plasma Fractionation Market Value Forecast, by End-user, 2020–2026

         13.4.1. Hospitals and Clinics

         13.4.2. Clinical Research Laboratories

         13.4.3. Academic Institutes 

     13.5. Latin America Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2020–2026

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

     13.6. Latin America Plasma Fractionation Market Attractiveness Analysis 

            13.6.1. By Product

            13.6.2. By Application

            13.6.3. By End-user

              13.6.4. Country 

14. Middle East & Africa Plasma Fractionation Market Analysis and Forecast

     14.1. Introduction

     14.2. Middle East & Africa Plasma Fractionation Market Value Forecast, by Product Type, 2020–2026

            14.2.1. Immunoglobulin

                 14.2.1.1. Intravenous Immunoglobulin

                 14.2.1.2. Subcutaneous Immunoglobulin

            14.2.2. Coagulation Factor Concentrates

                 14.2.2.1. Factor VIII

                 14.2.2.2. Factor IX

                 14.2.2.3. Factor XIII 

                 14.2.2.4. Prothrombin Complex Concentrates

                 14.2.2.5. Von Willebrand Factor (VWF)

                 14.2.2.6. Fibrinogen Concentrates

            14.2.3. Albumin

            14.2.4. Protease Inhibitors

            14.2.5. Other Plasma Products

     14.3. Middle East & Africa Plasma Fractionation Market Value Forecast, by Application, 2020–2026

            14.3.1. Neurology

            14.3.2. Immunology

            14.3.3. Hematology

            14.3.4. Critical Care

            14.3.5. Pulmonology

            14.3.6. Other Applications

     14.4. Middle East & Africa Plasma Fractionation Market Value Forecast, by End-user, 2020–2026

            14.4.1. Hospitals and Clinics

            14.4.2. Clinical Research Laboratories

            14.4.3. Academic Institutes

     14.5. Middle East & Africa Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2020–2026

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

     14.6. Middle East & Africa Plasma Fractionation Market Attractiveness Analysis

            14.6.1. By Product

            14.6.2. By Application

            14.6.3. By End-user

              14.6.4. Country 

15. Competition Landscape

     15.1. Market Player – Competition Matrix (By Tier and Size of companies)

     15.2. Company Profiles

            15.2.1. CSL Limited 

                 15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.2.1.2. Financial Overview

                 15.2.1.3. Product Portfolio

                 15.2.1.4. SWOT Analysis

                 15.2.1.5. Strategic Overview

            15.2.2. Shire plc

                 15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.2.2.2. Financial Overview

                 15.2.2.3. Product Portfolio

                 15.2.2.4. SWOT Analysis

                 15.2.2.5. Strategic Overview

            15.2.3. Sanquin

                 15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.2.3.2. Financial Overview

                 15.2.3.3. Product Portfolio

                 15.2.3.4. SWOT Analysis

                 15.2.3.5. Strategic Overview

            15.2.4. Biotest AG.

                 15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.2.4.2. Financial Overview

                 15.2.4.3. Product Portfolio

                 15.2.4.4. SWOT Analysis

                 15.2.4.5. Strategic Overview

            15.2.5. GRIFOLS

                 15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.2.5.2. Financial Overview

                 15.2.5.3. Product Portfolio

                 15.2.5.4. SWOT Analysis

                 15.2.5.5. Strategic Overview

            15.2.6. Baxter International Inc.

                 15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.2.6.2. Financial Overview

                 15.2.6.3. Product Portfolio

                 15.2.6.4. SWOT Analysis

                 15.2.6.5. Strategic Overview

            15.2.7. Kedrion

                 15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.2.7.2. Financial Overview

                 15.2.7.3. Product Portfolio

                 15.2.7.4. SWOT Analysis

                 15.2.7.5. Strategic Overview

            15.2.8. Octapharma

                15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.2.8.2. Financial Overview

                 15.2.8.3. Product Portfolio

                 15.2.8.4. SWOT Analysis

                 15.2.8.5. Strategic Overview

            15.2.9. China Biologic Products Holdings, Inc.

                 15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.2.9.2. Financial Overview

                 15.2.9.3. Product Portfolio

                 15.2.9.4. SWOT Analysis

                 15.2.9.5. Strategic Overview

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Plasma Fractionation Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2026